on Heidelberg Pharma AG (isin : DE000A11QVV0)
Heidelberg Pharma to Showcase Its ADC Innovations in November 2024
Heidelberg Pharma AG, a developer of innovative Antibody Drug Conjugates (ADCs), will present its latest ADC candidates and technology platforms at prominent conferences in November 2024. Based in Ladenburg, Germany, the company focuses on treatments for various cancers using its advanced ADCs.
HDP-101, an Amanitin-based ADC candidate, is in a Phase I/IIa trial targeting multiple myeloma. Recent findings highlighted a case of complete remission after 11 treatment cycles. HDP-201, an Exatecan-based ADC, targets GCC in gastrointestinal tumors and is set for clinical development in colorectal cancer.
Heidelberg Pharma will participate in the World ADC San Diego from November 4-7 and at the Deutsches Eigenkapitalforum in Frankfurt from November 25-27. These events will allow the company to share advancements in ADC technology with the scientific and financial communities.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news